S&P 500   3,980.35 (+0.01%)
DOW   31,580.63 (+0.00%)
QQQ   298.28 (-0.23%)
AAPL   155.01 (-0.61%)
MSFT   257.35 (-0.29%)
META   160.47 (+0.05%)
GOOGL   108.72 (-0.67%)
AMZN   128.42 (-0.82%)
TSLA   285.24 (+0.54%)
NVDA   137.18 (+0.03%)
NIO   17.43 (-0.29%)
BABA   88.94 (-1.83%)
AMD   81.48 (+2.35%)
T   16.84 (-0.18%)
MU   54.46 (-0.98%)
CGC   3.41 (+0.00%)
F   15.17 (-1.69%)
GE   73.19 (-0.53%)
DIS   111.75 (-0.83%)
AMC   8.43 (+0.48%)
PYPL   95.19 (+0.23%)
PFE   46.37 (+0.52%)
NFLX   225.00 (-1.73%)
S&P 500   3,980.35 (+0.01%)
DOW   31,580.63 (+0.00%)
QQQ   298.28 (-0.23%)
AAPL   155.01 (-0.61%)
MSFT   257.35 (-0.29%)
META   160.47 (+0.05%)
GOOGL   108.72 (-0.67%)
AMZN   128.42 (-0.82%)
TSLA   285.24 (+0.54%)
NVDA   137.18 (+0.03%)
NIO   17.43 (-0.29%)
BABA   88.94 (-1.83%)
AMD   81.48 (+2.35%)
T   16.84 (-0.18%)
MU   54.46 (-0.98%)
CGC   3.41 (+0.00%)
F   15.17 (-1.69%)
GE   73.19 (-0.53%)
DIS   111.75 (-0.83%)
AMC   8.43 (+0.48%)
PYPL   95.19 (+0.23%)
PFE   46.37 (+0.52%)
NFLX   225.00 (-1.73%)
S&P 500   3,980.35 (+0.01%)
DOW   31,580.63 (+0.00%)
QQQ   298.28 (-0.23%)
AAPL   155.01 (-0.61%)
MSFT   257.35 (-0.29%)
META   160.47 (+0.05%)
GOOGL   108.72 (-0.67%)
AMZN   128.42 (-0.82%)
TSLA   285.24 (+0.54%)
NVDA   137.18 (+0.03%)
NIO   17.43 (-0.29%)
BABA   88.94 (-1.83%)
AMD   81.48 (+2.35%)
T   16.84 (-0.18%)
MU   54.46 (-0.98%)
CGC   3.41 (+0.00%)
F   15.17 (-1.69%)
GE   73.19 (-0.53%)
DIS   111.75 (-0.83%)
AMC   8.43 (+0.48%)
PYPL   95.19 (+0.23%)
PFE   46.37 (+0.52%)
NFLX   225.00 (-1.73%)
S&P 500   3,980.35 (+0.01%)
DOW   31,580.63 (+0.00%)
QQQ   298.28 (-0.23%)
AAPL   155.01 (-0.61%)
MSFT   257.35 (-0.29%)
META   160.47 (+0.05%)
GOOGL   108.72 (-0.67%)
AMZN   128.42 (-0.82%)
TSLA   285.24 (+0.54%)
NVDA   137.18 (+0.03%)
NIO   17.43 (-0.29%)
BABA   88.94 (-1.83%)
AMD   81.48 (+2.35%)
T   16.84 (-0.18%)
MU   54.46 (-0.98%)
CGC   3.41 (+0.00%)
F   15.17 (-1.69%)
GE   73.19 (-0.53%)
DIS   111.75 (-0.83%)
AMC   8.43 (+0.48%)
PYPL   95.19 (+0.23%)
PFE   46.37 (+0.52%)
NFLX   225.00 (-1.73%)

Best Stocks Under $5.00 Right Now

Best Stocks Under $5.00

Like any group of stocks, penny stocks require discerning between price and value

There is a primal attraction to stocks priced under $5. These stocks are also known as penny stocks. Some purists will suggest that penny stocks have to trade for less than $1. However, in recent years, investors generally accept the definition that any stock that consistently trades below $5 fits into the category of penny stocks.

In this article, we’ll explain why stocks under $5 are considered penny stocks and whether investors should invest in penny stocks at all. We’ll also outline some of the risks and the rewards of buying stocks under $5. And we’ll provide some tips for successfully trading these stocks.

What Are Penny Stocks?

As mentioned above, penny stocks are stocks that trade for $5 or less. This definition means there are many options for investors including dollar stocks, penny stocks, and stocks that sell for fractions of one penny.

One stereotype about penny stocks is that every company is a startup that is in a risky market sector. However, there are many established businesses trading on standard exchanges that trade for less than $5 per share. When these companies appear on major exchanges, they are viewed as carrying less risk because they have to meet regulatory requirements that keep their accounting transparent.

That being said, penny stocks are usually small-cap companies (i.e. those with a market capitalization of less than $2 billion) that are either new to the market or undervalued and not recognized by investors. There tend to be fewer shares of these stocks available, meaning there is usually a wider spread between bids and asking prices.

And because penny stocks are generally considered to be speculative investments, they carry a certain element of risk. But it’s this risk that provides the opportunity for investors to make significant gains.

Should Investors Buy Stocks Under $5?

A broader question might be, “Should you buy stocks at all?” The answer to both questions is the same: It depends. You should not buy stocks if you don’t have a discriminating sense of how to invest money, or if you don’t have guidance around the topic from someone who does.

With the right knowledge, stocks are an excellent investment, and according to some estimates, far more sound than real estate. Yes, stock prices do fluctuate (sometimes wildly), but over the last several decades, they have outperformed real estate in some regards.

And investors who know what they’re doing with stocks can make huge gains, build enormous wealth, and create exponential financial success. Stocks under $5, in particular, present an incredible opportunity to make huge gains.

It all comes down to research.

You never want to sink all of your investment cash into just one basket. Estimates vary on the exact percentage, but most experts agree that the majority of your portfolio should be invested in solid, stable companies. That said, stocks under $5 can be a good place to do a little value investing and give some growth to your cash.

It’s important to keep in mind that there are many trading strategies in relation to the stock market, and investing in undervalued, up-and-coming companies is only one strategy. For example, some investors prefer to focus on stocks that pay out dividends, where each share pays out dividend payments of company profit—and a large number of shares creates a solid cash flow. Other investors like to buy shares in specific industries, like tech stocks, or they may choose to ride the market as they engage in the ups and downs of day trading, flipping stocks for profit.

Whichever stock trading strategy you prefer, penny stocks can be some of the best growth stocks for their undervalued cost—if you trade the right way.

What Are the Rewards of Buying Stocks Under $5?

As mentioned, penny stocks present huge opportunities for growth. Take True Religion as an example—an apparel company based in Vancouver, Canada. This designer-jeans outfit was trading for $0.67 per share in July of 2004. Just nine years later, TowerBrook Capital Partners acquired the company and paid $32 for every share...a whopping 4676% profit.

Can you think of any “normal stocks” that offered investors the same gains? They’re few and far between (though they do exist). These are the types of profit margins that traders dream of earning.

Another advantage of penny stocks is that they can be an easy way for small-time investors to enter the market. You don’t necessarily have to sink everything into some sort of risky biotech company. There are plenty of brand-name companies that are trading at under $5. Purchasing shares of these recognized businesses could be your chance to enter the stock market in an affordable way—and cash out big if things work out.

It’s not just about price, but about volume: A $500 investment might only buy you 5-10 shares of a recognizable blue-chip stock or it could buy you 100+ shares of a stock priced at $5 and below. If that company grows and becomes a mid-cap stock, you’ll see a lot more profit than you would have by investing in a more “normal” stock.

For that very same reason, penny stocks may allow you to diversify your holdings to a greater extent, with less money (if you want to eschew mutual funds and pick stocks yourself). With just $100 in the market, you could buy ten shares of stock in ten different industries.

What Are the Risks of Buying Stocks Under $5?

Many stocks under $5 are companies that may be startups or riskier business ventures. One of the biggest examples is biotech, an industry with larger startup costs and huge risks for investors. A startup company may discover the cure for cancer, in which case, you can cash out as a billionaire. Or, they may not, and they’ll take all your money with them when they fold.

Another disadvantage to stocks under $5 is that they may be stocks of a company that’s about to go bankrupt. They could be desperately selling shares of stock to raise money, or to help their executives bail out with a parachute built from your investment. Newly formed startups may also be on the verge of bankruptcy, and because of their lack of established history, no one may even know.

Occasionally penny stocks will be part of a “pump and dump” scam, where investors build excitement over a particular stock to drive up the price. They may “leak” information that a startup energy company struck gold or put forth an imaginative but enticing earnings estimate for the next quarter. As the stock value climbs out of control (far beyond the actual value of the market cap), hoodwinked investors pour their dollars into the company. Then it crashes, and the only ones who benefit are the scammers who bought into the stock before they made it popular.

Another more prosaic risk of stocks under $5 is that they may just not go anywhere, hovering under $5 for years on end. While this is certainly better than losing all your money, it’s not so conducive to portfolio growth.

Yet another disadvantage to stocks under $5 is their low trading volume. They can be harder to unload if you need to, because you may not find a willing buyer. Moreover, many penny stocks of younger upstart companies will most likely not pay out dividends. You are only purchasing the stock to leverage a change in its price—or hoping that in the future they will play into your dividend investing strategy.

As you can see, there are some risks and volatility associated with stocks under $5. However, it once again all comes down to playing it smart and doing your research. There are plenty of resources which will tell you about the most volatile stocks, along with providing stats to gauge their future possibilities.

If you have a good head for what’s going on, you won’t fall for scams or pour all your money into a pipe dream. The best traders know which stocks to watch; they understand the ins and outs of dividend yield and market capitalization—and can leverage these stats into higher amounts of revenue. There’s no secret to what they’re doing. They’re actively learning and keeping their eyes on the best times to buy stocks at 52 week low points. They know when to hold their assets, and when to sell them.

How to Trade Stocks Under $5?

Some stocks under $5 are traded on the New York Stock Exchange and NASDAQ. However, most stocks under $5 trade through over the counter transactions (OTC). Everything about these OTC transactions is done electronically through the OTC Bulletin Board (OTCBB). Companies that are traded on the OTCBB must still meet requirements from the SEC and FINRA. However, these companies don’t meet the requirements for trading on a larger market.

There are still more stocks under $5 that don’t even meet the requirements to be traded on the OTCBB. These stocks can be found on a listing service called Pink Sheets (so named because the stocks were once listed on pink sheets of paper). These companies are too small to be listed on a national exchange, or may not wish to make their accounting statements public—which means they don’t have to file with the SEC, and can’t be listed on a publicly-traded market.

As you might expect, these Pink Sheet stocks can carry significant risks. They can be difficult to analyze because of the lack of transparency around their business; investors should use caution and due diligence when purchasing them.

What Are the Best Stocks Under $5?

Now that we’ve reviewed the pros and cons of stocks under $5 and explained how they work, let’s address the question that every investor wants to know: how do I actualize this information?

It can be hard to find good stocks under $5, particularly in bull markets. This is a time when stocks frequently hit new all-time highs, and the price-to-earnings ratios of most S&P 500 companies make purchasing shares look like an expensive proposition. For these and other reasons, many investors have trouble finding low-priced stocks that haven't already appreciated greatly.  In more normal markets, a typical S&P 500 company trades at about fifteen times their earnings.

However, value investing opportunities do exist—if you're looking in the right places. Putting together a list of the best stocks under $5 requires investors to look at smaller and riskier companies in sectors that are either undiscovered or unrecognized by the market as a whole. When looking at cheap stocks to buy, some of them may not look especially attractive today, but long-term investors will recognize profit if they are willing to exercise patience and hold onto shares of these companies through multiple economic cycles.

Some of these companies are solid investing ideas because they are small. As a result, they’re considered too risky to attract the interest of most managed mutual funds and Wall Street money managers. Others operate in unrecognized or untested areas of the market. You may find even find crypto stocks, marijuana stocks, and bitcoin stocks on this list. Others have been beaten up by Mr. Market after a long period of slowing profits but are now actively trying to turn around their business and bounce back.

This low-priced list of stocks showcases a lot of different industries, but these picks all carry two common characteristics: They all have a super-low share price of $5.00 or less, and they all consistently receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts.


CymaBay Therapeutics stock logo

#1 - CymaBay Therapeutics

NASDAQ:CBAY
Stock Price: $3.69 (+$0.16)
PE Ratio: -2.84
Market Cap: $312.47 million
Average Trading Volume: 398,838 shares
Consensus Rating: Buy (3 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $11.00 (198.1% Upside)
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.
Secure Energy Services stock logo

#2 - Secure Energy Services

OTCMKTS:SECYF
Stock Price: $4.03 (-$0.12)
Average Trading Volume: 7,384 shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $8.58 (113.0% Upside)
Secure Energy Services Inc., an energy services company, provides solutions to upstream oil and natural gas companies operating primarily in Western Canadian Sedimentary Basin and the United States. It operates through two segments, Midstream Infrastructure, and Environmental and Fluid Management. The company's Midstream Infrastructure segment provides services, such as clean oil terminalling, rail transloading, pipeline transportation, marketing and custom treating of crude oil, produced and waste water disposal, oilfield waste processing, and purchase/resale of oil services through its full service terminals, rail facilities, crude oil pipelines, crude oil terminalling facilities, water disposal facilities, and landfills. The Environmental and Fluid Management segment includes a network of owned, operated, and marketed industrial landfills, hazardous and non-hazardous waste management and disposal, onsite abandonment, and environmental solutions for site remediation and reclamation, bio-remediation, water treatment and recycling, emergency response, rail, and metal recycling services, as well as offers fluid management for drilling, completion, and production operations for oil and gas producers. This segment also designs and implements drilling fluid systems for producers drilling for oil, bitumen, and natural gas; provides naturally occurring radioactive material management services, as well as equipment and chemical solutions that optimize well production. Secure Energy Services Inc. is headquartered in Calgary, Canada.
Tamarack Valley Energy stock logo

#3 - Tamarack Valley Energy

OTCMKTS:TNEYF
Stock Price: $2.89 (-$0.15)
Average Trading Volume: 103,998 shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $6.86 (137.4% Upside)
Tamarack Valley Energy Ltd. acquires, explores, develops, and produces crude oil, natural gas, and natural gas liquids in the Western Canadian sedimentary basin. It primarily holds interests in the Clearwater assets covering an area of approximately 357 sections of land located in Alberta; Charlie Lake assets covering approximately 357 sections of land in the northwestern area of Alberta; Viking light oil play in central and southern Alberta and west central Saskatchewan; Barons Sand oil play in the Penny area of southern Alberta; and heavy oil properties. The company was formerly known as Tango Energy Inc. and changed its name to Tamarack Valley Energy Ltd. in June 2010. Tamarack Valley Energy Ltd. was incorporated in 2002 and is headquartered in Calgary, Canada.
ADMA Biologics stock logo

#4 - ADMA Biologics

NASDAQ:ADMA
Stock Price: $2.87 (+$0.08)
PE Ratio: -6.83
Market Cap: $563.55 million
Average Trading Volume: 2.67 million shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $5.30 (84.7% Upside)
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Cidara Therapeutics stock logo

#5 - Cidara Therapeutics

NASDAQ:CDTX
Stock Price: $0.68 (+$0.01)
PE Ratio: -0.62
Market Cap: $46.95 million
Average Trading Volume: 323,905 shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $6.45 (848.5% Upside)
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.
89bio stock logo

#6 - 89bio

NASDAQ:ETNB
Stock Price: $4.75
PE Ratio: -0.91
Market Cap: $96.66 million
Average Trading Volume: 469,150 shares
Consensus Rating: Buy (8 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $23.75 (400.0% Upside)
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
CES Energy Solutions stock logo

#7 - CES Energy Solutions

OTCMKTS:CESDF
Stock Price: $1.83 (+$0.02)
Average Trading Volume: 42,019 shares
Consensus Rating: Buy (9 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $3.93 (114.9% Upside)
CES Energy Solutions Corp., together with its subsidiaries, designs, implements, and manufactures advanced consumable fluids and specialty chemicals. It provides solutions for drill-bit, point of completion and stimulation, wellhead and pump-jack, and pipeline and midstream markets. The company's solutions include corrosion inhibitors, demulsifiers, H2S scavengers, paraffin control products, surfactants, scale inhibitors, biocides, and other specialty products. It also designs and implements drilling fluid systems and completion solutions for oil and gas producers; designs and manufactures production and specialty chemicals for use in the oil and natural gas production markets, the stimulation and fracturing markets, and the pipeline and midstream markets; and operates trucks and trailers to transport products in the oil and gas industry. In addition, the company provides environmental consulting, water management services, and drilling fluids waste disposal services primarily to oil and gas producers; and laboratory services. It serves oil and natural gas industry, including multinational producers, intermediate oil and natural gas operators, independent juniors, and joint ventures, as well as pipeline and mid-stream markets in western Canada and the United States. The company was formerly known as Canadian Energy Services & Technology Corp. and changed its name to CES Energy Solutions Corp. in June 2017. CES Energy Solutions Corp. was incorporated in 1986 and is headquartered in Calgary, Canada.
UserTesting stock logo

#8 - UserTesting

NYSE:USER
Stock Price: $4.07 (+$0.06)
Market Cap: $586.00 million
Average Trading Volume: 329,196 shares
Consensus Rating: Buy (10 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $11.00 (170.3% Upside)
UserTesting, Inc. engages in the operation of a software-as-a-service (SaaS) platform that enables organizations to know experiences of people as they engage with products, designs, apps, processes, concepts, or brands in the United States, the United Kingdom, and internationally. Its platform captures customer perspectives from targeted audiences who share their thoughts for digital, real-world, or omnichannel experiences. The company sells through a direct selling motion with field sales representatives; and inside sales organization that sells to mid-market, and small and medium-sized business customers. It serves customers in B2B and B2C technology, health and fitness, retail and apparel, travel and hospitality, financial services, automotive and transportation, food and beverage, consumer products, and other industries. The company was incorporated in 2007 and is based in San Francisco, California.
VTEX stock logo

#9 - VTEX

NYSE:VTEX
Stock Price: $4.11 (+$0.10)
PE Ratio: -10.54
Market Cap: $769.64 million
Average Trading Volume: 995,068 shares
Consensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $11.08 (169.7% Upside)
VTEX provides software-as-a-service digital commerce platform for enterprise brands and retailers. Its platform enables customers to execute their commerce strategy, including building online stores, integrating, and managing orders across channels, and creating marketplaces to sell products from third-party vendors. It has operations in Brazil, Argentina, Chile, Colombia, France, Italy, Mexico, Peru, Portugal, Romania, Spain, the United Kingdom, and the United States. VTEX was founded in 2000 and is headquartered in London, the United Kingdom.
Hecla Mining stock logo

#10 - Hecla Mining

NYSE:HL
Stock Price: $3.95 (-$0.09)
PE Ratio: -19.75
Market Cap: $2.13 billion
Average Trading Volume: 4.69 million shares
Dividend Yield: 0.65%
Consensus Rating: Buy (2 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $6.75 (70.9% Upside)
Hecla Mining Company, together with its subsidiaries, discovers, acquires, develops, and produces precious and base metal properties in the United States and internationally. The company mines for silver, gold, lead, and zinc concentrates, as well as carbon material containing silver and gold for sale to custom smelters, metal traders, and third-party processors,; and doré containing silver and gold. It owns 100% interests in the Greens Creek mine located on Admiralty Island in southeast Alaska; the Lucky Friday mine situated in northern Idaho; the Casa Berardi mine located in the Abitibi region of northwestern Quebec, Canada; and the San Sebastian mine situated in the city of Durango, Mexico. The company also holds 100% interests in the Fire Creek mine located in Lander County, Nevada; and the Hollister and Midas mines situated in Elko County, Nevada. Hecla Mining Company was incorporated in 1891 and is headquartered in Coeur d'Alene, Idaho.
Terran Orbital stock logo

#11 - Terran Orbital

NYSE:LLAP
Stock Price: $3.95 (-$0.04)
Market Cap: $542.30 million
Average Trading Volume: 176,408 shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $13.40 (239.2% Upside)
Terran Orbital Corporation manufactures, owns, and operates satellites and related space-based solutions that provide earth observation, data and analytics to defense, intelligence, civil, and commercial end users in the United States. The company operates through two segments, Satellite Solutions and Earth Observation Solutions. The Satellite Solutions segment offers end-to-end satellite solutions, including spacecraft design, development, launch services, and on-orbit operations for critical missions across a range of applications in various orbits to governmental agencies and commercial businesses. The Earth Observation Solutions segment develops, builds, launches, and operates a constellation of earth observation satellites that has synthetic aperture radar and electro-optical capabilities to provide earth observation data and mission solutions. It also provides secondary payload solutions and onboard data processing capabilities on its satellite constellation, including sensors, optical links, or other mission solutions. The company was founded in 2013 and is headquartered in Boca Raton, Florida.
Helix Energy Solutions Group stock logo

#12 - Helix Energy Solutions Group

NYSE:HLX
Stock Price: $4.13 (-$0.11)
PE Ratio: -5.29
Market Cap: $626.65 million
Average Trading Volume: 1.51 million shares
Consensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $7.25 (75.5% Upside)
Helix Energy Solutions Group, Inc., an offshore energy services company, provides specialty services to the offshore energy industry primarily in Brazil, the Gulf of Mexico, North Sea, the Asia Pacific, and West Africa regions. The company operates through three segments: Well Intervention, Robotics, and Production Facilities. It engages in the installation of flowlines, control umbilicals, and manifold assemblies and risers; trenching and burial of pipelines; installation and tie-in of riser and manifold assembly; commissioning, testing, and inspection activities; and provision of cable and umbilical lay, and connection services. The company also provides well intervention, intervention engineering, and production enhancement services; inspection, repair, and maintenance of production structures, trees, jumpers, risers, pipelines, and subsea equipment; and related support services. In addition, it offers reclamation and remediation services; well plug and abandonment services; pipeline abandonment services; and site inspections. Additionally, the company offers oil and natural gas processing facilities and services; and fast response system, as well as site clearance and subsea support services. It serves independent oil and gas producers and suppliers, pipeline transmission companies, renewable energy companies, and offshore engineering and construction firms. The company was formerly known as Cal Dive International, Inc. and changed its name to Helix Energy Solutions Group, Inc. in March 2006. Helix Energy Solutions Group, Inc. was incorporated in 1979 and is headquartered in Houston, Texas.
Solo Brands stock logo

#13 - Solo Brands

NYSE:DTC
Stock Price: $4.24 (-$0.07)
PE Ratio: -84.80
Market Cap: $402.21 million
Average Trading Volume: 719,490 shares
Consensus Rating: Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $22.17 (422.8% Upside)
Solo Brands, Inc. operates a direct-to-consumer platform that offers outdoor lifestyle branded products in the United States. The company provides camp stoves under the Solo Stove Lite brand name; fire pits under the Solo Stove brand name; grills, cook tops, and tools; kayaks under the Oru brand name; paddle boards under the ISLE brand name; and storage solutions for fire pits, firewood, and other accessories. It also offers swim trunks, casual shorts, sport products, polos, shirts, and lounge products under the Chubbies brand name; consumables, such as color packs, starters, natural charcoal, and firewood products; and accessories comprising shelters, shields, roasting sticks, tools, paddles, and pumps under the Solo Stove, Oru, and ISLE brands. The company was founded in 2011 and is headquartered in Grapevine, Texas.
Valens Semiconductor stock logo

#14 - Valens Semiconductor

NYSE:VLN
Stock Price: $4.45 (+$0.17)
PE Ratio: -3.80
Market Cap: $436.68 million
Average Trading Volume: 243,299 shares
Consensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $12.00 (169.7% Upside)
Valens Semiconductor Ltd. engages in the provision of semiconductor products that enables high-speed video and data transmission for the audio-video and automotive industries. It offers HDBaseT technology, which enables the simultaneous delivery of ultra-high-definition digital video and audio, Ethernet, USB, control signals, and power through a single long-reach cable. The company offers audio-video solutions for the enterprise, education, digital signage, medical and residential, and industrial markets; and automotive solutions, which provide chipsets that support advanced driver-assistance systems, automated driving systems, infotainment, telecommunications, and basic connectivity. It serves customers through distributors and representatives in Israel, China, Hong Kong, the United States, Mexico, Japan, and internationally. The company was incorporated in 2006 and is headquartered in Hod Hasharon, Israel.
Sunlight Financial stock logo

#15 - Sunlight Financial

NYSE:SUNL
Stock Price: $2.98 (-$0.03)
PE Ratio: -2.14
Market Cap: $390.08 million
Average Trading Volume: 821,347 shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $6.80 (128.2% Upside)
Sunlight Financial Holdings Inc. operates a business-to-business-to-consumer technology-enabled point-of-sale financing platform in the United States. Its platform is used to provide secured and unsecured loans for homeowners originated by third-party lenders to purchase and install residential solar energy systems, and other home improvements. The company was founded in 2014 and is based in Charlotte, North Carolina.
Lineage Cell Therapeutics stock logo

#16 - Lineage Cell Therapeutics

NYSEAMERICAN:LCTX
Stock Price: $1.34 (+$0.01)
PE Ratio: -4.47
Market Cap: $227.48 million
Average Trading Volume: 256,003 shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $6.00 (347.8% Upside)
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
Stereotaxis stock logo

#17 - Stereotaxis

NYSEAMERICAN:STXS
Stock Price: $1.96 (-$0.04)
PE Ratio: -7.84
Market Cap: $146.59 million
Average Trading Volume: 196,170 shares
Consensus Rating: Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $8.40 (328.6% Upside)
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. Stereotaxis, Inc. markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to develop a magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was incorporated in 1990 and is headquartered in Saint Louis, Missouri.
Integra Resources stock logo

#18 - Integra Resources

NYSEMKT:ITRG
Stock Price: $0.60 (+$0.02)
PE Ratio: -1.37
Market Cap: $46.16 million
Average Trading Volume: 97,598 shares
Consensus Rating: Buy (3 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $4.13 (584.1% Upside)
Integra Resources Corp., a mineral resources company, engages in the acquisition, exploration, and development of mineral properties in the Americas. It primarily focuses on the development of DeLamar project that consists of DeLamar and Florida Mountain gold and silver deposits comprising 790 unpatented lode, placer, and millsite claims, as well as 16 tax parcels covering an area of approximately 8,673 hectares located in the Owyhee County, south western Idaho. The company was formerly known as Mag Copper Limited and changed its name to Integra Resources Corp. in August 2017. Integra Resources Corp. was incorporated in 1997 and is headquartered in Vancouver, Canada.
Viant Technology stock logo

#19 - Viant Technology

NASDAQ:DSP
Stock Price: $4.75 (-$0.01)
PE Ratio: -8.48
Market Cap: $288.90 million
Average Trading Volume: 65,911 shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $11.40 (140.0% Upside)
Viant Technology Inc. operates as an advertising software company. It provides Adelphic, an enterprise software platform that enables marketers and their advertising agencies to plan, buy, and measure advertising across channels, including desktop, mobile, connected and linear TV, in-game, streaming audio, and digital billboards. The company also offers Holistic, an omnichannel demand side platform for marketers and their agencies to manage omnichannel campaigns and access metrics from each channel to inform decisions in other channels; Viant Household ID, a household profile, which provides household insights for optimized bid decisions and touchpoint collection across consumer pathways, as well as offers holistic targeting and measurement across channels; World Without Cookies software to manage reach and frequency at the household level; and Viant Identity Graph, which reduces or eliminates the need for cookies by enabling matching of people-based identifiers that anchor digital identifiers that allows marketers to reach targeted consumers in a privacy-conscious manner. In addition, it provides Data lake, a software and self-service enables customers with differentiated insights, including conversion lift, multi-touch attribution, foot-traffic data reports, digital-out-of-home lift, sales reporting, and ROAS analytics; onboarding data integrations provides marketers with high match rates to audience insights for segmentation, targeting, and measuring outcomes; and self-service interface that provides customers with transparency and control over their advertising campaigns and underlying data infrastructure. The company sells its platform through a direct sales team focused on business development in various markets. It serves purchasers of programmatic advertising inventory; and large, independent, and mid-market advertising agencies. The company was founded in 1999 and is headquartered in Irvine, California.
Provention Bio stock logo

#20 - Provention Bio

NASDAQ:PRVB
Stock Price: $4.81 (-$0.01)
PE Ratio: -2.92
Market Cap: $308.03 million
Average Trading Volume: 1.08 million shares
Consensus Rating: Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $18.33 (281.2% Upside)
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.
Quipt Home Medical stock logo

#21 - Quipt Home Medical

NASDAQ:QIPT
Stock Price: $4.88 (+$0.10)
PE Ratio: 81.35
Market Cap: $165.19 million
Average Trading Volume: 87,912 shares
P/E Ratio: 81.3
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $10.31 (111.3% Upside)
Quipt Home Medical Corp. provides in-home medical equipment and supplies, and respiratory and durable medical equipment in the United States. The company also offers management of various chronic disease states focusing on patients with heart and pulmonary disease, sleep disorders, reduced mobility, and other chronic health conditions. In addition, it provides nebulizers, oxygen concentrators, CPAP and BiPAP units, ventilator equipment and aids, daily and ambulatory aides, equipment solutions, power wheelchairs, oxygen therapy, bariatric equipment, bathroom safety products, bilevel positive airway pressure, canes/crutches, continuous positive airway pressure, CPAP masks and accessories, hospital beds, humidifiers, compressors, patient lifts, walkers, products for wound care, and medical equipment for home-based sleep apnea and chronic obstructive pulmonary disease treatments, as well as rents respiratory equipment. The company was formerly known as Protech Home Medical Corp. and changed its name to Quipt Home Medical Corp. in May 2021. Quipt Home Medical Corp. was incorporated in 1993 and is headquartered in Wilder, Kentucky.
Immunic stock logo

#22 - Immunic

NASDAQ:IMUX
Stock Price: $4.73 (+$0.13)
PE Ratio: -1.56
Market Cap: $144.60 million
Average Trading Volume: 84,344 shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $24.40 (415.9% Upside)
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.
Lightning eMotors stock logo

#23 - Lightning eMotors

NYSE:ZEV
Stock Price: $2.20 (-$0.11)
PE Ratio: -12.22
Market Cap: $166.36 million
Average Trading Volume: 688,299 shares
Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $8.13 (269.3% Upside)
Lightning eMotors, Inc. designs, manufactures, and sells zero-emission commercial fleet vehicles and powertrains to commercial fleets, large enterprises, original equipment manufacturers, and governments in the United States. It offers zero-emission class 3 to 7 battery electric and fuel cell electric vehicles. The company's vehicles comprise cargo and passenger vehicles, school buses, ambulances, shuttle buses, work trucks, city buses, and motorcoaches. It also offers charging systems and charging infrastructure solutions for commercial medium duty vans and motorcoach fleets. The company was founded in 2008 and is headquartered in Loveland, Colorado.
Roivant Sciences stock logo

#24 - Roivant Sciences

NASDAQ:ROIV
Stock Price: $3.62 (+$0.14)
PE Ratio: -2.26
Market Cap: $2.54 billion
Average Trading Volume: 818,088 shares
Consensus Rating: Buy (8 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $11.86 (227.5% Upside)
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Compass Therapeutics stock logo

#25 - Compass Therapeutics

NASDAQ:CMPX
Stock Price: $3.13 (+$0.08)
PE Ratio: -7.82
Market Cap: $317.04 million
Average Trading Volume: 80,010 shares
Consensus Rating: Buy (8 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target: $10.00 (219.5% Upside)
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

More Stock Ideas from MarketBeat

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.